LLY
LLY
Eli Lilly and Company
$1,210.50
+$18.76 (+1.57%)
Mkt Cap: $1.14T
Home / LLY / News

Incretin Surge Drives Guidance Raise: Scale Secures Moat (LLY Q1 2026 Earnings Call)

By Dr. Graph | Updated on May 26, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Eli Lilly and Company started fiscal year 2026 with outstanding financial momentum as robust demand for its cardiometabolic portfolio drove significant top-line expansion and prompted a full-year guidance upgrade. The company achieved critical pipeline milestones during the quarter, including key regulatory approvals and clinical successes that strengthen its long-term competitive moat. By investing aggressively in scaling production and diversifying its therapeutic assets, the pharmaceutical leader is positioning itself to capture a massive global metabolic market.

Surge in Metabolic Demand Delivers 56% Revenue Growth

Eli Lilly delivered 56% year-over-year revenue growth in the first quarter of fiscal 2026, showcasing high patient demand for its core metabolic treatments. The company recorded non-GAAP earnings per share of $8.55, reflecting robust operational efficiency driven by top-line growth. Gross margin as a percentage of revenue reached 82.6%, a decrease of approximately one percentage point due to lower net prices.

Upgraded Annual Outlook Reflects Strong Underlying Incretin Momentum

Strong operational momentum prompted Lucas Montarce to raise full-year revenue guidance to between $82 billion and $85 billion. This updated projection represents a 28% growth rate at the midpoint compared to the prior year. Highlighting this progress, David Ricks stated, "During the quarter, we delivered robust revenue growth, advanced our pipeline across all 4 therapeutic areas, announced multiple business development transactions and invested to drive our future growth."

Key Non-Incretin Products Drive 160% Collective Growth

Mounjaro and Zepbound (referred to as Suven in the transcript) generated $12.8 billion in combined global revenue, driven by strong market uptake. Within the key products portfolio, immunology, oncology, and neuroscience medicines collectively grew by 160% due to expanded patient starts and label expansions. Total prescriptions in the U.S. obesity incretin market grew by over 80%, fueled by the approval of oral treatments.

Competitor Launches and Price Adjustments Unlock Global Growth Levers

David Ricks clarified that 75% of international Mounjaro volume is currently paid out-of-pocket, indicating price-elastic demand that expands significantly with lower prices. Patrik Jonsson reported that Mounjaro prescriptions rose 10% in India following local generic semaglutide launches, proving that competitor entries can stimulate overall market expansion. Additionally, Ilya Yuffa highlighted that the upcoming Medicare bridge program will cap senior out-of-pocket costs at $50 per month, which should improve long-term patient persistence.

Disclaimer: This report is for informational purposes only and does not constitute financial or investment advice. Always conduct your own research or consult a qualified professional before investing. Past performance is not indicative of future results.

Frequently Asked Questions

What clinical results did Koundeo achieve in the cardiovascular safety trials?
In the ACHIEVE IV Phase III registration trial, Koundeo met its primary endpoint by demonstrating a 16 percent lower risk of MACE 4 events compared to insulin glargine. It also achieved a 23 percent lower risk in MACE 3 events and demonstrated a 57 percent survival advantage in a preplanned survival analysis.
How did Retatrutide perform in its first Phase III trial for type 2 diabetes?
In the TRANSCEND T2D-1 study, Retatrutide reduced HbA1c by an average of 1.7 to 2.0 percentage points. Additionally, study participants achieved significant average weight loss ranging from 11.1 to 16.6 kilograms.
What did the latest Phase III data show for Egis in pediatric patients?
In the Phase III adorable trial for children as young as six months with moderate to severe atopic dermatitis, 63 percent of patients achieved EASI-75 skin improvement. Furthermore, 44 percent of pediatric patients achieved clear or almost clear skin.

More from LLY

earnings

Incretin Volume Surges: Pipeline Expansion Secures Market Leadership (LLY Q1 2026 Earnings Call)

Eli Lilly started fiscal year 2026 with outstanding financial momentum as robust demand for its cardiometabolic portfolio drove significant top-line expansion. The company achieved critical pipeline milestones during the quarter, including key regulatory approvals and clinical successes that strengthen its long-term competitive moat. By investing aggressively in scaling production and diversifying its therapeutic assets, the pharmaceutical leader is positioning itself to capture a massive global metabolic market.

catalyst

Lilly’s Insilico AI Licensing Deal Expands Oral Pipeline Reach

Eli Lilly’s expanded AI drug discovery partnership with Insilico matters because it monetizes Lilly’s disease expertise into faster preclinical output, while shifting financial risk via milestone-contingent payments tied to regulatory and commercial success.